Regeneron Pharmaceuticals, Inc.
Close on Nov 20, 2026Market cap $95.24BP/E 20.3Yield –
Regeneron Pharmaceuticals Indirect R&D by Quarter
Indirect R&D — Lab Supplies and Other Research and Development Costs ($M) ($M)
Regeneron Pharmaceuticals Indirect R&D: $76.3M in Q3 2026, up 13.0% from a year earlier. That is the highest of the 34 quarters on record here.
Where the Q3 2026 figure comes from
“R&D Expenses Table (FY2026Q3): Lab supplies and other research and development costs | 76.3 | 67.5 | 8.8 | 207.1 | 192.4 | 14.7”
Source: Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗
Reported in Form 10-Q / 10-K MD&A — Research and Development Expenses Summary Table.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Regeneron Pharmaceuticals Indirect R&D ($M), quarterly Q2 2018–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rd-indirect-lab
See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.
See a number that looks wrong?